Core Insights - Kneat.com, inc. has reinforced its leadership position in the life sciences sector by achieving the highest-ever number of new customer wins in 2025, alongside significant revenue growth and advancements in its technology platform [1][12]. Financial Performance - Fourth-quarter revenues increased by 24% to CAD 17.0 million, compared to CAD 13.7 million in Q4 2024 [6][7]. - Software-as-a-Service (SaaS) revenue grew by 29% to CAD 16.2 million in Q4 2025, up from CAD 12.5 million in Q4 2024 [6][7]. - For the full year 2025, total revenues rose by 29% to CAD 63.3 million, compared to CAD 48.9 million in 2024 [7]. - Annual Recurring Revenue (ARR) reached CAD 74.1 million at the end of 2025, marking a 24% increase from CAD 59.7 million at the end of 2024 [6][7]. - Kneat achieved positive Adjusted EBITDA of CAD 4.2 million in Q4 2025, compared to CAD 2.6 million in Q4 2024 [7][19]. Customer Acquisition and Satisfaction - In 2025, Kneat achieved a record year for new customer acquisitions, including nine major strategic wins, representing over 300,000 employees across various life sciences sectors [12]. - The Kneat Gx platform was recognized as the 1 Pharma and Biotech Software by G2, earning a customer satisfaction score of 98/100 [8]. Strategic Developments - Kneat entered a significant partnership with Capgemini to enhance digital validation across global manufacturing networks [12]. - The company expanded its leadership team with key appointments to strengthen its long-term vision and commitment to innovation [12]. Operational Outlook - Kneat anticipates continued growth in 2026, expecting to outpace the incremental ARR achieved in 2025, despite typical second-half seasonality [11]. - The company aims for cash-flow breakeven in 2026, supported by a solid balance sheet and operational momentum [15].